Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study to Assess the Efficacy and Safety of Disease modifying treatments in Patients with Multiple Sclerosis in Real-life Set-up: The Austrian MS Treatment Registry (AMSTR)

Trial Profile

A Study to Assess the Efficacy and Safety of Disease modifying treatments in Patients with Multiple Sclerosis in Real-life Set-up: The Austrian MS Treatment Registry (AMSTR)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 26 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dimethyl fumarate (Primary) ; Fingolimod (Primary) ; Natalizumab (Primary) ; Teriflunomide (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Nov 2021 Primary endpoint (annualized relapse rates (ARR) during treatment with FTY, DMF or TERI over 2 years after initiation of therapy) has been met, according to Results published in the Journal of Neurology.
    • 01 Nov 2021 Results published in the Journal of Neurology
    • 12 Oct 2018 Results (N=664) assessing efficacy, frequencies and reasons for treatment interruption of fingolimod, dimethyl fumarate or teriflunomide, presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top